Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study

References

• WHO. Global report on psoriasis. Geneva: World Health Organization; 2016.
   Google Scholar
• Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–708.
   PubMed Web of Science ®Google Scholar
• Daudén E, Castañeda S, Suarez C, et al. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermosiliogr. 2012;103(Supl 1):1–64.
   PubMedGoogle Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
   PubMed Web of Science ®Google Scholar
• Dauden E, Puig L, Ferrandiz C, the Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30(Suppl 2):1–18.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.e1-30.
   PubMed Web of Science ®Google Scholar
• Norlin JM, Calara PS, Persson U, et al. Real-world outcomes in 2646 psoriasis patients: one in five has PASI >/=10 and/or DLQI >/=10 under ongoing systemic therapy. J Dermatol Treat. 2017;28(6):500–504.
   PubMed Web of Science ®Google Scholar
• Jungo P, Maul JT, Djamei V, et al. Superiority in quality of life improvement of biologics over conventional systemic drugs in a Swiss Real-Life Psoriasis Registry. Dermatology (Basel, Switzerland). 2016;232(6):655–663.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Callis DK, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487–494.
   PubMedGoogle Scholar
• Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. Giornale Italiano di Dermatologia e Venereologia: organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia. 2016;151(6):663–677.
   PubMed Web of Science ®Google Scholar
• Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ (Clinical Research ed). 2016;354:i4428.
   PubMedGoogle Scholar
• Maybury CM, Porter HF, Kloczko E, et al. Prevalence of advanced liver fibrosis in patients with severe psoriasis. JAMA Dermatol. 2019;155(9):1028.
   PubMed Web of Science ®Google Scholar
• Fiore M, Leone S, Maraolo AE, et al. Liver illness and psoriatic patients. Biomed Res Int. 2018;2018:3140983.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17(2):217.
   PubMed Web of Science ®Google Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020; 19(1):102429.
   PubMed Web of Science ®Google Scholar
• Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52(3 Pt 1):434–444.
   PubMed Web of Science ®Google Scholar
• Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21–29.
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol. 2008;35(7):1454–1457.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, de la Cueva P, Ara M, et al. Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations. Actas Dermosifiliogr. 2016;107(3):194–206.
   PubMed Web of Science ®Google Scholar
• Fernández-Torres RM, Pita-Fernández S, Fonseca E. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain. Int J Dermatol. 2014;53(11):e507–e511.
   PubMed Web of Science ®Google Scholar
• AEDV. How to measure psoriasis severity?. Spanish Academy of Dermatology and Venereology. 2016.
   Google Scholar
• Langley RGB, Feldman SR, Nyirady J, et al. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venerol. 2012;92(5):497–501.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–1140.
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508.
   PubMedGoogle Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281.e4.
   PubMed Web of Science ®Google Scholar
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Maybury CM, Jabbar-Lopez ZK, Wong T, et al. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol. 2014;171(1):17–29.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Bonanad C, Dauden E, en nombre del Grupo de Trabajo en Inflamación Sistémica en Psoriasis, et al. Psoriasis and nonalcoholic fatty liver disease. Actas Dermosifiliogr. 2017;108(6):506–514.
   PubMed Web of Science ®Google Scholar
• Caballeria L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol. 2010;22(1):24–32.
   PubMed Web of Science ®Google Scholar
• Hagstrom H, Talback M, Andreasson A, et al. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology. 2020;158(1):200–214.
   PubMed Web of Science ®Google Scholar
• Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010;10(1):40.
   PubMed Web of Science ®Google Scholar
• Caballeria L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol. 2018;16(7):1138–1145.e5.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30(2):282–287.
   PubMed Web of Science ®Google Scholar
• Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778–786.
   PubMed Web of Science ®Google Scholar
• Wenk K, Arrington K, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25(4):383–391.
   PubMed Web of Science ®Google Scholar
• Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662.
   PubMed Web of Science ®Google Scholar
• Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46(6):1111–1118.
   PubMed Web of Science ®Google Scholar